



ASX & Media Release

8 August 2022

Retirement of Non-Executive Chair

Melbourne, Australia; 8 August 2022: Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, announces that the Company’s long standing Chair, Mr John Read has advised that he will be retiring as the Non-Executive Chair and as a Director of Patrys, effective from the close of business on Wednesday, 31 August 2022. Mr Michael Stork will be appointed as interim Chair while a search for a new Chair, which is currently underway, is completed.

Mr Read was the inaugural Chair of Patrys when it listed on the ASX in 2007, and has served for 15 years in this role. During this time Mr Read has played a pivotal leadership role, most recently guiding the Company’s development of its unique deoxymab antibody technology platform. Mr Read has supported and worked closely with the current CEO, Dr James Campbell, to expand the portfolio of clinical applications and partnerships for Patrys’ deoxymab technology. With the recent completion of a successful engineering run of PAT-DX1, Mr Read has led the Company to a point where it has a clear line-of-sight to initiating its first clinical trial of a deoxymab in H2 CY2023.

Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said: “John has made a sustained and significant contribution to Patrys since his appointment as Chair in May 2007. Patrys has transformed considerably under John’s stewardship, and he leaves the Company in a strong position and with a clear trajectory to becoming a clinical-stage company. On a personal front, I am very grateful for John’s knowledge, support, expertise, wise counsel and guidance over the years. On behalf of the Board, I would like to extend my heartfelt thanks to John and wish him every success in his future endeavours.”

Patrys Chair, Mr John Read commented: “It has been an absolute privilege to be part of the Patrys leadership team since the Company’s listing on the ASX in 2007. I am particularly proud of our progress in advancing the deoxymab platform in preparation for its first in human clinical trial planned for H2 CY23. I am indebted to my fellow directors and Patrys’ CEO, Dr James Campbell, for their wisdom, professionalism and dedication. With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new Chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company.”

Patrys has already commenced a search for a new Chair to lead the Company through the next stage of its growth as it evolves towards becoming a clinical-stage therapeutic antibody company. Mr Mike Stork will act as interim Chair until such time as a new Chair is appointed.

-Ends-

This announcement is authorised for release by the Board of Directors of Patrys Limited.



For further information, please contact:

General enquiries

James Campbell
Chief Executive Officer
P: +61 3 96703273
info@patrys.com

Media enquiries:

Haley Chartres
HACK
P: +61 423 139 163
haley@hck.digital

Registered Office Address

Level 4, 100 Albert Road
South Melbourne VIC 3205

About Patrys Limited

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at www.patrys.com.

About Patrys' deoxymab platform:

Patrys' deoxymab platform is based on the deoxymab antibody that was first identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus (SLE). While most antibodies bind to cell surface markers, deoxymab penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes. Cancer cells often have high levels of mutations and underlying deficiencies in the DNA repair mechanisms. For these reasons, the additional inhibition of the DNA repair processes by deoxymab can kill cancer cells, but appears to have little impact on normal cells. As a single agent, deoxymab has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, deoxymabs can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours.

Patrys has developed two humanised forms of deoxymab, both which have improved activity over the original deoxymab antibody. PAT-DX1 is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab, while PAT-DX3 is a full-sized IgG antibody. In a range of pre-clinical studies, PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumour explants, xenograft, and orthotopic models. PAT-DX1 has been shown to cross the blood brain barrier, reduce tumour size, and increase survival in multiple animal models of brain cancer, other cancers, and cancer metastases. PAT-DX1 is tumour-agnostic, meaning that it can target many different tumour types in the body, regardless of specific tumour antigens. Patrys believes that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic, and ovarian cancers.

Patrys has completed proof of concept studies showing that it is possible to conjugate small molecule payloads to PAT-DX3, and is advancing antibody drug conjugate (ADC) efforts using deoxymabs. In addition, deoxymabs such as PAT-DX1 and PAT-DX3 can be used to target nanoparticles carrying a



payload of anti-cancer drugs specifically to tumours. This allows specific delivery of cancer drugs to multiple types of cancer while having minimal impact on normal, healthy cells.

Patrys' rights to deoxymab 3E10 are part of a worldwide license to develop and commercialise a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University as anti-cancer and diagnostic agents. Overall, eight patents in the portfolio have been granted with six patents covering the unconjugated form of deoxymab 3E10 (and derivatives thereof) have already been granted (Europe, Japan, China, and 3 in the USA), and two patents covering nanoparticle conjugation (Australia and India).